Amgen licenses neurotrophic agents from Guilford:
This article was originally published in Clinica
Executive Summary
Amgen has bought the worldwide rights to all human diagnostic and therapeutic applications of Guilford Pharmaceutical's FKBP-neuroimmunophilin ligands, a novel class of small molecule neurotrophic agents. Amgen will pay $35 million initially and $13.5 million over three years to support research at Guilford, plus milestone payments (of up to $392 million) and royalties. Amgen will develop, manufacture and market the products worldwide.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.